null

null

null

null

null

null

null

null

null

1.63x Total Debt / Equity (Elevated leverage)

Low direct sensitivity; EBR is pre-revenue/early-revenue medtech with equity-funded operations, minimal floating-rate debt exposure

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Piezoelectric crystal components sourced from Asia-Pacific; 2) Implantable-grade electronics from concentrated European/US semiconductor suppliers

Primary revenue in USD (US trials); European CE-mark markets expose EUR/GBP devaluation risk; limited revenue base makes devaluation impact modest but margin-compressive

Primarily US-based operations; CE-mark approval targets Germany/UK/Netherlands; EUR and GBP devaluation risk material as European commercialization scales

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High; single-source suppliers for implantable ultrasound transducer components likely represent >30% input cost with no near-term substitutes given FDA/CE qualification requirements

Medical device hardware company; cloud dependency minimal — device operates independently; 30-day cloud termination would disrupt data analytics/remote monitoring but not core therapy delivery

Any cloud disruption affects physician-facing data portal and remote programming support tools, creating temporary workflow disruption but not patient safety failure

Low API coupling risk; proprietary wireless pacing protocol is internally developed; no meaningful third-party API dependency in core product architecture

Very low; revenue model is medical device sales/licensing, not investment contracts; no profit-sharing or token-based structures triggering Howey Test concern

Very High

Moderate; cardiac patient data collected in EU trials triggers GDPR compliance obligations; US patient data subject to HIPAA primarily; CCPA exposure limited given B2B hospital sales model

Low; EBR operates in niche WiSE cardiac resynchronization therapy market with minimal market share; no dominant position triggering antitrust scrutiny

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional device sales; multi-year hospital contracts emerging but <20% of revenue currently recurring; service/support contracts nascent

Capital equipment sale of implantable pulse generator plus per-procedure consumable electrode; potential service contract attach as install base grows

ASP estimated $15,000–$25,000 per system; pricing anchored to CRT-D competitive set; reimbursement coding risk is primary stress point — CPT/DRG coverage gaps could force discounting

Moderate; unique wireless CRT technology commands premium over wired alternatives but hospital budget constraints and reimbursement uncertainty cap pricing power at 4/10

30.3% Gross Margin (Moderate (20-40%))

Low free-rider risk; implantable device requires physician training, hospital capital approval, and ongoing support — high friction prevents casual adoption or abandonment

Headcount-linear in near term; scaling requires additional field clinical engineers (1 per ~5–8 implanting centers), so doubling revenue roughly requires 60–70% headcount increase

High marginal cost currently; each new hospital activation requires clinical support staff, physician training, and inventory placement — cost structure improves only at significant scale (>500 centers)

Not applicable; EBR does not operate a franchise model

At 10x scale, CAC likely compresses as brand recognition grows among electrophysiologists; but hospital capital committee cycles remain long — CAC payback stays 18–36 months minimum

Weak network effects; physician referral networks and KOL advocacy create modest data/reputation flywheel, but product utility does not increase with user base size

-50.1% Return on Assets (Negative equity)

Moderate resilience; cardiac resynchronization therapy addresses life-threatening heart failure — demand is medically driven but hospital capital budgets contract in recessions, delaying adoption

Hospital electrophysiology and heart failure programs at Tier 1 academic medical centers and large regional cardiology practices

Interventional cardiologists and cardiac electrophysiologists who are KOLs driving peer adoption; concentration risk high — top 20 implanting physicians likely represent >50% of early volume

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

227.8% CapEx / Revenue (High-CapEx Infrastructure)

0001347123

EBRCZ